Belgian Communications Stock News

As the European markets experience a mix of modest gains and losses, with indices like Germany's DAX and Italy's FTSE MIB showing resilience against a backdrop of economic recovery, investors are increasingly on the lookout for opportunities that may be undervalued. In this context, identifying stocks trading below their intrinsic value can offer potential avenues for growth, especially when supported by strong fundamentals and favorable market conditions.

As the European markets show resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are increasingly considering dividend stocks to enhance their portfolios. In this context, selecting stocks with a strong track record of consistent dividend payouts can be an effective strategy for those looking to balance growth and income in today's dynamic market environment.

As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...

Key Insights The projected fair value for Cenergy Holdings is €16.15 based on 2 Stage Free Cash Flow to Equity Cenergy...

As the European markets experience a mix of resilience and fluctuation, with the STOXX Europe 600 Index showing gains supported by solid economic data, investors are increasingly looking at dividend stocks as a potential source of stable income. In light of these market dynamics, selecting dividend stocks that offer consistent payouts and align well with current economic conditions can be an effective strategy for building a robust portfolio.

What VGP’s latest bond moves could mean for shareholders VGP (ENXTBR:VGP) has just completed a capped tender offer for part of its 1.625% green bonds due January 2027, alongside issuing new €600 million 4% senior unsecured green notes due 2032. See our latest analysis for VGP. These refinancing moves come as the share price sits at €105.00, with a 30 day share price return of 6.82% and a year to date share price return of 7.91%. The 1 year total shareholder return of 42.65% contrasts with a...

SCR-Sibelco: recent performance in focus SCR-Sibelco (ENXTBR:094426466) is drawing attention after a period where the share price shows a 12% year to date decline, with shorter term moves over the past week and month also negative. See our latest analysis for SCR-Sibelco. With the share price at €4,800.00 and a 7 day share price return of an 11.93% decline, recent weakness adds to a year to date share price return of an 11.93% decline, while the 1 year total shareholder return of a 4% decline...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

If you are wondering whether KBC Group's current share price lines up with its underlying value, you are not alone. That is exactly what this article is going to unpack. The stock last closed at €117.90, with returns of 2.8% over 7 days, 5.4% over 30 days, 3.9% year to date, 66.7% over 1 year, 99.8% over 3 years and 158.8% over 5 years. This naturally raises questions about what is already priced in and what might still be on the table. Recent news coverage around KBC Group has focused on...

If you are wondering whether Umicore is priced attractively right now, it helps to step back and look at what the recent share performance and current valuation are really telling you. The share price is at €19.04, with a 2.0% decline over the last 7 days, a 9.1% gain over 30 days, a 2.4% gain year to date, an 88.6% gain over 1 year, and declines of 39.7% and 55.7% over 3 and 5 years respectively, which together provide mixed signals about growth potential and risk. Recent coverage around...

Earlier this week, UCB Canada Inc. announced that Health Canada granted a Notice of Compliance for PrBIMZELX® (bimekizumab injection) to treat adult patients with moderate to severe hidradenitis suppurativa who have not responded adequately to conventional systemic therapy, based on positive results from two pivotal Phase III trials. This approval marks the fifth indication for PrBIMZELX® in Canada, underscoring UCB’s push to broaden the drug’s role across chronic inflammatory conditions in...

By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger...

Berenberg recently initiated research coverage on D'Ieteren Group, assigning a positive view and emphasizing the company’s concentrated portfolio and core holding in Belron. The broker’s focus on structural growth, resilient cash generation, and the impact of D'Ieteren’s 2024 shareholder reorganization brings fresh attention to the group’s long-term value creation profile. We’ll now examine how Berenberg’s emphasis on Belron as the key value driver shapes D'Ieteren Group’s broader investment...

VGP NV has completed a capped tender offer of €100,000,000 for part of its outstanding €500,000,000 1.625% green bonds due January 2027, following the successful satisfaction of the new issue condition linked to its recent €600,000,000 4% senior unsecured green notes due January 16, 2032. By retiring a portion of shorter-dated green debt while issuing longer-term notes, VGP is actively reshaping the timing and composition of its funding mix. We’ll now examine how VGP’s refinancing move,...

Melexis NV ( EBR:MELE ) shareholders should be happy to see the share price up 17% in the last month. But over the last...

argenx (ENXTBR:ARGX) shares are in focus after the U.S. FDA accepted a priority review for a supplemental Biologics License Application for VYVGART in acetylcholine receptor antibody seronegative generalized myasthenia gravis. See our latest analysis for argenx. argenx shares have been relatively soft in recent months, with a 30 day share price return of a 4.07% decline and a year to date return of a 3.70% decline, even though the 1 year total shareholder return of 8.74% and 3 year total...

NV Bekaert's (EBR:BEKB) stock is up by a considerable 16% over the past three months. As most would know, fundamentals...

Barco (ENXTBR:BAR) is back on investors’ radar after recent share price moves, with the stock showing a small gain over the month but a negative return over the past 3 months. See our latest analysis for Barco. That recent 2.8% 1 month share price return, after a 6.2% 3 month share price decline, sits against a 1 year total shareholder return of 33.8%, while the 3 and 5 year total shareholder returns remain negative. If Barco has you rethinking opportunities in tech hardware and displays, it...

With a price-to-earnings (or "P/E") ratio of 24.2x Elia Group SA/NV ( EBR:ELI ) may be sending very bearish signals at...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? In a...

DEME Group recently took delivery of its second new wind turbine installation vessel, Norse Energi, from CIMC Raffles Shipyard, a purpose-built ship designed to handle next-generation large-scale offshore wind turbines and equipped with advanced lifting, loading, and sustainable technologies. By pairing Norse Energi with sister vessel Norse Wind, DEME Group further reinforces its specialized offshore wind installation fleet, potentially strengthening its role in large, complex renewable...

argenx SE recently announced that the FDA has accepted for priority review a supplemental Biologics License Application for VYVGART to treat adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, supported by Phase 3 ADAPT SERON data showing statistically significant improvements in daily living scores versus placebo. This priority review, with a PDUFA action date set for May 10, 2026, could materially broaden VYVGART’s reach across previously underserved...

Umicore (ENXTBR:UMI) has drawn fresh attention after a recent move in its share price, with the stock showing a one-month return of 20.18% and a three-month return of 9.93%. See our latest analysis for Umicore. Set against a one-year total shareholder return of 104.17% and a three-year total shareholder return decline of 38.63%, the recent 20.18% one-month share price return suggests short term momentum has picked up while longer term performance remains weak. If Umicore’s move has you...